Abstract
Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010-March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included. Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5% males (P = 0.259), no significant difference in comorbidities (P >.05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9% (95% CI, 69.9 to 81.8), and 84.0% (95% CI, 78.1 to 89.9) for Moxifloxacin (difference-8.1%, 95% CI,-16.5-.003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9%, (95% CI, 88.3 – 95.6), and 95.5% (95% CI, 91.8-99.2) for moxifloxacin (difference-3.5%, 95% CI,-8.7-1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929). Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 878-886 |
| Number of pages | 9 |
| Journal | Journal of Infection in Developing Countries |
| Volume | 12 |
| Issue number | 10 |
| DOIs | |
| State | Published - Oct 1 2018 |
Fingerprint
Keywords
- CAP
- Community-associated pneumonia
- Levofloxacin
- Moxifloxacin
- Speed of recovery
ASJC Scopus subject areas
- Parasitology
- Microbiology
- Infectious Diseases
- Virology
Cite this
Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin. / Ramahi, Jamal Wadi Al; Ramadan, Mustafa; Jaber, Waad; Abushanab, Lamya; Mughrabi, Mohammad; Alshamayleh, Noor; Mulhem, Ahmad; Momani, Dania; Obaidat, Mohammad; Haddad, Ghayda; Khalil, Basma; Zahran, Anas; Odat, Esraa; Kufoof, Nadeen; Arabiat, Haneen; Diab, Amr; Anzueto, Antonio R.
In: Journal of Infection in Developing Countries, Vol. 12, No. 10, 01.10.2018, p. 878-886.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Speed of recovery in adult patients with community-acquired pneumonia; moxifloxacin versus levofloxacin
AU - Ramahi, Jamal Wadi Al
AU - Ramadan, Mustafa
AU - Jaber, Waad
AU - Abushanab, Lamya
AU - Mughrabi, Mohammad
AU - Alshamayleh, Noor
AU - Mulhem, Ahmad
AU - Momani, Dania
AU - Obaidat, Mohammad
AU - Haddad, Ghayda
AU - Khalil, Basma
AU - Zahran, Anas
AU - Odat, Esraa
AU - Kufoof, Nadeen
AU - Arabiat, Haneen
AU - Diab, Amr
AU - Anzueto, Antonio R
PY - 2018/10/1
Y1 - 2018/10/1
N2 - Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010-March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included. Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5% males (P = 0.259), no significant difference in comorbidities (P >.05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9% (95% CI, 69.9 to 81.8), and 84.0% (95% CI, 78.1 to 89.9) for Moxifloxacin (difference-8.1%, 95% CI,-16.5-.003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9%, (95% CI, 88.3 – 95.6), and 95.5% (95% CI, 91.8-99.2) for moxifloxacin (difference-3.5%, 95% CI,-8.7-1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929). Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5.
AB - Introduction: To evaluate the speed of recovery in CAP-treated adults with Moxifloxacin versus levofloxacin. Methodology:A retrospective multicenter study between January 14, 2010-March 23, 2017. Patients' records with the diagnosis of community-acquired pneumonia (CAP), age ≥ 18 and ≤ 60 years old, susceptible bacteria to the prescribed fluoroquinolone, completed three days of antimicrobial therapy and who were switched from parenteral to the oral form for the same antimicrobial agent were included. Results: 701 charts were reviewed, 367 were excluded; not on respiratory fluoroquinolones (RFQ), age > 60 or < 18 years old, not enough data, prior antimicrobials, hospital-associated pneumonia, < 3 days of therapy, and one pregnant woman. 334 patients were Included; 167 levofloxacin and 167 moxifloxacin, with 68.5% males (P = 0.259), no significant difference in comorbidities (P >.05), but increased diabetes mellitus in moxifloxacin-treated patients (P = 0.012). No significant difference in Pneumonia Severity Index (PSI). Multivariate and univariate analysis demonstrated that day 3 rate of improvement; levofloxacin-treated patients 75.9% (95% CI, 69.9 to 81.8), and 84.0% (95% CI, 78.1 to 89.9) for Moxifloxacin (difference-8.1%, 95% CI,-16.5-.003, P = 0.058). And day 5 rates of improvement in Levofloxacin-treated patients was 91.9%, (95% CI, 88.3 – 95.6), and 95.5% (95% CI, 91.8-99.2) for moxifloxacin (difference-3.5%, 95% CI,-8.7-1.7, P = 0.184). There was no significant difference for patients with radiological diagnoses for day 3 (P = 0.832) and 5 (P = 0.929). Conclusions: Our uni-and-multivariate analyses demonstrated that moxifloxacin exhibited no significant differences in the rates of improvement on days 3 and 5.
KW - CAP
KW - Community-associated pneumonia
KW - Levofloxacin
KW - Moxifloxacin
KW - Speed of recovery
UR - http://www.scopus.com/inward/record.url?scp=85061016270&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85061016270&partnerID=8YFLogxK
U2 - 10.3855/jidc.10335
DO - 10.3855/jidc.10335
M3 - Article
AN - SCOPUS:85061016270
VL - 12
SP - 878
EP - 886
JO - Journal of Infection in Developing Countries
JF - Journal of Infection in Developing Countries
SN - 1972-2680
IS - 10
ER -